Study Preview
Study Title and Description
Burch colposuspension versus fascial sling to reduce urinary stress incontinence.
Key Questions Addressed
1 | Sling vs Comparator RCT outcomes (excluding AEs) | |
2 | Sling Adverse Events |
Primary Publication Information
Title | Burch colposuspension versus fascial sling to reduce urinary stress incontinence. |
Author | Albo ME |
Country | -- |
Year | 2007 |
Numbers |
Pubmed ID: 17517855 20084 (internal) |
Secondary Publication Information
UI | Title | Author | Country | Year | |
---|---|---|---|---|---|
Complications in women undergoing Burch colposuspension versus autologous rectus fascial sling for stress urinary incontinence | Chai TC, Albo ME, Richter HE, Norton PA, Dandreo KJ, Kenton K, Lowder JL, Stoddard AM | -- | 2009 | ||
Changes in urodynamic measures two years after Burch colposuspension or autologous sling surgery | Kraus SR, Lemack GE, Richter HE, Brubaker L, Chai TC, Albo ME, Sirls LT, Leng WW, Kusek JW, Norton P, Litman HJ | -- | 2011 | ||
Design of the Stress Incontinence Surgical Treatment Efficacy Trial (SISTEr) | Tennstedt S | -- | 2005 | ||
Quality of life after surgery for stress incontinence. | Tennstedt SL, Litman HJ, Zimmern P, Ghetti C, Kusek JW, Nager CW, Mueller ER, Kraus SR, Varner E | -- | 2008 | ||
5-year continence rates, satisfaction and adverse events of burch urethropexy and fascial sling surgery for urinary incontinence. | Brubaker L., Richter HE., Norton PA., Albo M., Zyczynski HM., Chai TC., Zimmern P., Kraus S., Sirls L., Kusek JW., Stoddard A., Tennstedt S., Gormley EA. | Department of Obstetrics and Gynecology, Loyola University Chicago, Stritch School of Medicine, Chicago, Illinois 60153, USA. L.Brubaker@lumc.edu | 2012 |
Extraction Form: Sling vs Comparator RCT outcomes (excluding AEs)
Arms
Number | Title | Description | Comments |
---|---|---|---|
1 | Burch | ||
2 | PVS, fascial |
Question... Follow Up | Answer | Follow-up Answer | |
---|---|---|---|
Trial Name | SISTEr | ||
Country | US | ||
Outcome Categories Reported | Objective SUI | ||
Subjective SUI | |||
Quality of life | |||
Sexual function | |||
OR outcomes/complications (not "AEs") | |||
Population (reason for surgery etc.) | Symptomatic SUI | ||
Urodynamic SUI | |||
Intrinsic sphincter deficiency | |||
Recurrent incontinence after surgery | |||
Mixed incontinence | |||
Concomitant prolapse surgery | |||
RCT Comparison Category | Pubovaginal sling vs. Other | ||
Multicenter | Yes | ||
Institution Type | Academic hospital | ||
Number of surgeons performing procedures | Not reported | ||
Surgeons' Training | Urogynecology | ||
Urology | |||
Residents or fellows performing surgery? | Unclear/Not reported | ||
Study Quality (overall) | A (good) | ||
Study Sponsor/Funding | Government |
Baseline Characteristics
Question | Burch | PVS, fascial | Burch | Fascial PVS | Total | Comments | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
Answer | Follow-up | Answer | Follow-up | Answer | Follow-up | Answer | Follow-up | Answer | Follow-up | ||
No. Randomized | 329 | 326 | |||||||||
Mean Age | 52.2 | 51.6 | |||||||||
Post-Op Follow-Up Interval (Maximum) | 24 mo | 24 mo |
Results & Comparisons
Results Data
Outcome: Overall treatment success Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | Burch vs. PVS, fascial |
24 months |
N Enrolled | 329 | 326 | 0.01 | |||
Percentage | 38 | 47 |
Outcome: Stress-specific success Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | Burch vs. PVS, fascial |
24 months |
N Enrolled | 329 | 326 | <0.001 | |||
Percentage | 49 | 66 |
Outcome: satisfaction Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | Burch vs. PVS, fascial |
24 months |
Percentage | 78 | 86 | 0.02 | |||
5 years |
N Enrolled | 172 | 179 | 0.04 | |||
Percentage | 73 | 83 |
Outcome: Return to normal voiding at discharge Population: All Participants | |||||
---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS |
0 weeks |
Percentage | 58 | 44 | ||
N Analyzed | 329 | 326 |
Outcome: Return to normal voiding at 6wk Population: All Participants | |||||
---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS |
6 weeks |
Percentage | 97 | 86 | ||
N Analyzed | 329 | 326 |
Outcome: Voiding dysfunction Population: All Participants | |||||
---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS |
6 weeks |
Percentage | 2 | 14 | ||
N Analyzed | 329 | 326 |
Outcome: Percent failed stress test Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | Burch vs. PVS, fascial |
24 months |
N Enrolled | 255 | 265 | <0.001 | |||
Percentage | 29 | 13 |
Outcome: Percent failed pad test Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | Burch vs. PVS, fascial |
24 months |
N Enrolled | 255 | 265 | 0.67 | |||
Percentage | 15 | 14 |
Outcome: Percent undergoing repeat surgical therapy Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | Burch vs. PVS, fascial |
24 months |
N Enrolled | 255 | 265 | <0.001 | |||
Percentage | 11 | 2 |
Outcome: Composite long-term success measure Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | ERROR vs. ERROR |
5 years |
N Enrolled | 174 | 183 | 0.002 | |||
Percentage | 24.1 | 30.8 |
Outcome: Subj cure Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | ERROR vs. ERROR |
5 years |
N Enrolled | 174 | 183 | 0.02 | |||
Counts | 71 | 94 |
Outcome: Cure Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | ERROR vs. ERROR |
5 years |
N Enrolled | 174 | 183 | 0.26 | |||
Counts | 81 | 91 |
Outcome: Never surgically retreated by 5 yrs Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | ERROR vs. ERROR |
5 years |
N Enrolled | 174 | 183 | p<0.0001 | |||
Percentage | 88 | 98 |
Outcome: Treated for de novo UUI between 2.5-5 yrs out Population: All Participants | |||||
---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS |
5 years |
N Enrolled | 174 | 183 | ||
Counts | 7 | 3 |
Outcome: Treated for persistent UUI between 2.5-5 yrs out Population: All Participants | |||||
---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS |
5 years |
N Enrolled | 174 | 183 | ||
Counts | 29 | 33 |
Outcome: Treated for prolapse between 2.5-5 yrs out Population: All Participants | |||||
---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS |
5 years |
N Enrolled | 174 | 183 | ||
Counts | 5 | 1 |
Outcome: Treated for voiding dysfunction between 2.5-5 yrs out Population: All Participants | |||||
---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS |
5 years |
N Enrolled | 174 | 183 | ||
Counts | 1 | 7 |
Outcome: IIQ improvement Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | Burch vs. PVS, fascial |
24 months |
N Analyzed | 329 | 326 | 0.52 | |||
Mean | -136.1 | -130.3 | |||||
Standard Deviation | 112.1 | 107.7 | |||||
5 years |
N Analyzed | 174 | 183 | 0.83 | |||
Mean | 43.1 | 44.8 | |||||
Standard Deviation | 68.2 | 79.6 |
Outcome: Lower urinary tract symptom distress Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | ERROR vs. ERROR |
5 years |
N Analyzed | 174 | 183 | 0.05 | |||
Mean | 50.2 | 40.2 | |||||
Standard Deviation | 50.9 | 45.8 |
Extraction Form: Sling Adverse Events
Arms
Number | Title | Description | Comments |
---|---|---|---|
1 | Burch | ||
2 | Fascial PVS |
Question... Follow Up | Answer | Follow-up Answer | |
---|---|---|---|
Study Type | RCT | ||
Sling Category | Pubovaginal (bladder neck) | ||
Adverse Event Ascertainment | Active | ||
Was the Clavien-Dindo Classification of Surgical Complications system used? | Yes | ||
Was a data safety monitoring board used? | Yes |
Results & Comparisons
Results Data
Outcome: Overall treatment success Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | Burch vs. PVS, fascial |
24 months |
N Enrolled | 329 | 326 | 0.01 | |||
Percentage | 38 | 47 |
Outcome: Stress-specific success Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | Burch vs. PVS, fascial |
24 months |
N Enrolled | 329 | 326 | <0.001 | |||
Percentage | 49 | 66 |
Outcome: satisfaction Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | Burch vs. PVS, fascial |
24 months |
Percentage | 78 | 86 | 0.02 | |||
5 years |
N Enrolled | 172 | 179 | 0.04 | |||
Percentage | 73 | 83 |
Outcome: Return to normal voiding at discharge Population: All Participants | |||||
---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS |
0 weeks |
Percentage | 58 | 44 | ||
N Analyzed | 329 | 326 |
Outcome: Return to normal voiding at 6wk Population: All Participants | |||||
---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS |
6 weeks |
Percentage | 97 | 86 | ||
N Analyzed | 329 | 326 |
Outcome: Voiding dysfunction Population: All Participants | |||||
---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS |
6 weeks |
Percentage | 2 | 14 | ||
N Analyzed | 329 | 326 |
Outcome: Percent failed stress test Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | Burch vs. PVS, fascial |
24 months |
N Enrolled | 255 | 265 | <0.001 | |||
Percentage | 29 | 13 |
Outcome: Percent failed pad test Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | Burch vs. PVS, fascial |
24 months |
N Enrolled | 255 | 265 | 0.67 | |||
Percentage | 15 | 14 |
Outcome: Percent undergoing repeat surgical therapy Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | Burch vs. PVS, fascial |
24 months |
N Enrolled | 255 | 265 | <0.001 | |||
Percentage | 11 | 2 |
Outcome: Composite long-term success measure Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | ERROR vs. ERROR |
5 years |
N Enrolled | 174 | 183 | 0.002 | |||
Percentage | 24.1 | 30.8 |
Outcome: Subj cure Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | ERROR vs. ERROR |
5 years |
N Enrolled | 174 | 183 | 0.02 | |||
Counts | 71 | 94 |
Outcome: Cure Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | ERROR vs. ERROR |
5 years |
N Enrolled | 174 | 183 | 0.26 | |||
Counts | 81 | 91 |
Outcome: Never surgically retreated by 5 yrs Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | ERROR vs. ERROR |
5 years |
N Enrolled | 174 | 183 | p<0.0001 | |||
Percentage | 88 | 98 |
Outcome: Treated for de novo UUI between 2.5-5 yrs out Population: All Participants | |||||
---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS |
5 years |
N Enrolled | 174 | 183 | ||
Counts | 7 | 3 |
Outcome: Treated for persistent UUI between 2.5-5 yrs out Population: All Participants | |||||
---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS |
5 years |
N Enrolled | 174 | 183 | ||
Counts | 29 | 33 |
Outcome: Treated for prolapse between 2.5-5 yrs out Population: All Participants | |||||
---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS |
5 years |
N Enrolled | 174 | 183 | ||
Counts | 5 | 1 |
Outcome: Treated for voiding dysfunction between 2.5-5 yrs out Population: All Participants | |||||
---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS |
5 years |
N Enrolled | 174 | 183 | ||
Counts | 1 | 7 |
Outcome: IIQ improvement Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | Burch vs. PVS, fascial |
24 months |
N Analyzed | 329 | 326 | 0.52 | |||
Mean | -136.1 | -130.3 | |||||
Standard Deviation | 112.1 | 107.7 | |||||
5 years |
N Analyzed | 174 | 183 | 0.83 | |||
Mean | 43.1 | 44.8 | |||||
Standard Deviation | 68.2 | 79.6 |
Outcome: Lower urinary tract symptom distress Population: All Participants | Between-Arm Comparisons | ||||||
---|---|---|---|---|---|---|---|
Time Point | Measure | Burch | PVS, fascial | Burch | Fascial PVS | Comparison Measure | ERROR vs. ERROR |
5 years |
N Analyzed | 174 | 183 | 0.05 | |||
Mean | 50.2 | 40.2 | |||||
Standard Deviation | 50.9 | 45.8 |
Adverse Events
Arm or Total | Title | Description | Follow-up time | In-hospital or After discharge | Is event serious? | Reported definition of serious event | Number affected | Number at risk (analyzed) | Difference between 2 slings (eg, OR/RR or %, with 95% CI) | Reported P value between slings | Comments |
---|---|---|---|---|---|---|---|---|---|---|---|
Burch | Organ injury in OR (urethra, bladder, bowel) | Ureteral injury | ND | ND | Yes | Dindo Grade 3-5 | 2 | 329 | ND | NS | |
Fascial PVS | ND | ND | Yes | Dindo Grade 3-5 | 0 | 326 | |||||
Total | |||||||||||
Burch | Fistula | Ureterovaginal fistula | ND | ND | Yes | Dindo Grade 3-5 | 1 | 329 | ND | NS | |
Fascial PVS | ND | ND | Yes | Dindo Grade 3-5 | 0 | 326 | |||||
Total | |||||||||||
Burch | Organ injury in OR (urethra, bladder, bowel) | Vaginotomy | ND | ND | Yes | Dindo Grade 3-5 | 1 | 329 | ND | NS | |
Fascial PVS | ND | ND | Yes | Dindo Grade 3-5 | 0 | 326 | |||||
Total | |||||||||||
Burch | Organ injury in OR (urethra, bladder, bowel) | Cystotomy | ND | ND | Yes | Dindo Grade 3-5 | 10 | 329 | ND | NS | |
Fascial PVS | ND | ND | Yes | Dindo Grade 3-5 | 2 | 326 | |||||
Total | |||||||||||
Burch | Suture erosion | Suture erosion into bladder | ND | ND | Yes | Dindo Grade 3-5 | 1 | 329 | ND | NS | |
Fascial PVS | ND | ND | Yes | Dindo Grade 3-5 | 0 | 326 | |||||
Total | |||||||||||
Burch | Infection, UTI | Recurrent cystitis leading to dx cysto | ND | ND | Yes | Dindo Grade 3-5 | 5 | 329 | ND | NS | |
Fascial PVS | ND | ND | Yes | Dindo Grade 3-5 | 6 | 326 | |||||
Total | |||||||||||
Burch | Infection, UTI | Pyelonephritis | ND | ND | Yes | Dindo Grade 3-5 | 1 | 329 | ND | NS | |
Fascial PVS | ND | ND | Yes | Dindo Grade 3-5 | 1 | 326 | |||||
Total | |||||||||||
Burch | Catheter complication | Catheter complication - clot requiring cystoscopy | ND | ND | Yes | Dindo Grade 3-5 | 1 | 329 | ND | NS | |
Fascial PVS | ND | ND | Yes | Dindo Grade 3-5 | 1 | 326 | |||||
Total | |||||||||||
Burch | Retention requiring surgery | Voiding dysfunction leading to surgical revision | ND | ND | Yes | Dindo Grade 3-5 | 0 | 329 | ND | ND | |
Fascial PVS | ND | ND | Yes | Dindo Grade 3-5 | 20 | 326 | |||||
Total | |||||||||||
Burch | Pain, unspecified area (new or different after surgery) | Pelvic pain | ND | ND | Yes | Dindo Grade 3-5 | 0 | 329 | ND | 0.25 | |
Fascial PVS | ND | ND | Yes | Dindo Grade 3-5 | 2 | 326 | |||||
Total | |||||||||||
Burch | Bleeding | Bleeding | ND | ND | Yes | Dindo Grade 3-5 | 3 | 329 | ND | 0.62 | |
Fascial PVS | ND | ND | Yes | Dindo Grade 3-5 | 1 | 326 | |||||
Total | |||||||||||
Burch | Wound complication | Wound complication requiring surgical intervention: incisional hernia, seroma or hematoma, infection | ND | ND | Yes | Dindo Grade 3-5 | 13 | 329 | ND | 0.83 | |
Fascial PVS | ND | ND | Yes | Dindo Grade 3-5 | 11 | 326 | |||||
Total | |||||||||||
Burch | Gastrointestinal | rectal injury (1) and constipation requiring surgical disimpaction (1) | ND | ND | Yes | Dindo Grade 3-5 | 1 | 329 | ND | 1.0 | |
Fascial PVS | ND | ND | Yes | Dindo Grade 3-5 | 1 | 326 | |||||
Total | |||||||||||
Burch | Respiratory distress | Requiring intubation | ND | ND | Yes | Dindo Grade 3-5 | 0 | 329 | ND | 0.50 | |
Fascial PVS | ND | ND | Yes | Dindo Grade 3-5 | 1 | 326 | |||||
Total | |||||||||||
Burch | Laryngospasm | Requiring intubation | ND | ND | Yes | Dindo Grade 3-5 | 0 | 329 | ND | 0.50 | |
Fascial PVS | ND | ND | Yes | Dindo Grade 3-5 | 1 | 326 | |||||
Total | |||||||||||
Burch | Infection, UTI | Cystitis | ND | ND | No | Dindo Grade 1-2 | 202 | 329 | ND | <0.001 | |
Fascial PVS | ND | ND | No | Dindo Grade 1-2 | 299 | 326 | |||||
Total | |||||||||||
Burch | Infection, UTI | Pyelonephritis | ND | ND | No | Dindo Grade 1-2 | 1 | 329 | ND | <0.001 | |
Fascial PVS | ND | ND | No | Dindo Grade 1-2 | 6 | 326 | |||||
Total | |||||||||||
Burch | DVT | ND | ND | No | Dindo Grade 1-2 | 0 | 329 | ND | 0.29 | ||
Fascial PVS | ND | ND | No | Dindo Grade 1-2 | 1 | 326 | |||||
Total | |||||||||||
Burch | Bleeding | Bleeding | ND | ND | No | Dindo Grade 1-2 | 5 | 329 | ND | 0.29 | |
Fascial PVS | ND | ND | No | Dindo Grade 1-2 | 8 | 326 | |||||
Total | |||||||||||
Burch | Wound complication | sling exposure (2), incisional hernia (3), superficial separation (15), seroma (24), infection (52), granulation tissue (44) | ND | ND | No | Dindo Grade 1-2 | 69 | 329 | ND | 0.69 | |
Fascial PVS | ND | ND | No | Dindo Grade 1-2 | 71 | 326 | |||||
Total | |||||||||||
Burch | Gastrointestinal | Ileus (7), Other (anal fisures, constipation, n/v, abd pain, etc) (8) | ND | ND | No | Dindo Grade 1-2 | 7 | 329 | ND | 0.80 | |
Fascial PVS | ND | ND | No | Dindo Grade 1-2 | 8 | 326 | |||||
Total | |||||||||||
Burch | Pulmonary | Atelectasis (10), pneumonia (3), pulm edema (2), other (4) | ND | ND | No | Dindo Grade 1-2 | 10 | 329 | ND | 1.0 | |
Fascial PVS | ND | ND | No | Dindo Grade 1-2 | 9 | 326 | |||||
Total | |||||||||||
Burch | Neurologic | Sciatica (2), numbness/weakness (7), vertigo (2) | ND | ND | No | Dindo Grade 1-2 | 6 | 329 | ND | 1.0 | |
Fascial PVS | ND | ND | No | Dindo Grade 1-2 | 5 | 326 | |||||
Total | |||||||||||
Burch | Cardiovascular | Bradycardia (1), ROMI (1) | ND | ND | No | Dindo Grade 1-2 | 0 | 329 | ND | 0.25 | |
Fascial PVS | ND | ND | No | Dindo Grade 1-2 | 2 | 326 | |||||
Total | |||||||||||
Burch | Constitutional | Fever unknown origin (2), hypokalemia (1) | ND | ND | No | Dindo Grade 1-2 | 3 | 329 | ND | .025 | |
Fascial PVS | ND | ND | No | Dindo Grade 1-2 | 0 | 326 | |||||
Total | |||||||||||
Burch | Allergic/hives | ND | ND | No | Dindo Grade 1-2 | 0 | 329 | ND | 0.25 | ||
Fascial PVS | ND | ND | No | Dindo Grade 1-2 | 2 | 326 | |||||
Total | |||||||||||
Burch | Dermatologic | Rash, erythema | ND | ND | No | Dindo Grade 1-2 | 2 | 329 | ND | 0.45 | |
Fascial PVS | ND | ND | No | Dindo Grade 1-2 | 4 | 326 | |||||
Total | |||||||||||
Burch | Postop UUI (total) | total treated, not de novo | 24 mo | After discharge | No | Dindo Grade 1-2 | 65 | 329 | ND | 0.04 | |
Fascial PVS | 24 mo | After discharge | No | Dindo Grade 1-2 | 87 | 326 | |||||
Total | |||||||||||
Burch | Postop UUI (de novo) | de novo treated, not total | 24 mo | After discharge | No | Dindo Grade 1-2 | 11 | 329 | ND | NS | |
Fascial PVS | 24 mo | After discharge | No | Dindo Grade 1-2 | 11 | 326 | |||||
Total |